xentuzumab (BI-836845) / Boehringer Ingelheim 
Welcome,         Profile    Billing    Logout  
 9 Diseases   1 Trial   1 Trial   127 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
xentuzumab (BI-836845) / Boehringer Ingelheim
NCT02145741: Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours

Hourglass Jan 2016 - Dec 2016 : For solid tumors (tumor type not specified) in Japanese patients
Completed
1
21
Japan
Xentuzumab, low dose, every week (qw), Xentuzumab, middle dose, qw, Xentuzumab, high dose, qw
Boehringer Ingelheim
Neoplasms
07/15
07/23
NCT02204072 / 2013-004011-41: BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Hourglass Jan 2017 - Dec 2017 : From combination trial of BI 836845 with enzalutamide for castration resistant prostate cancer
Completed
1
120
Europe, US, RoW
BI 836845, Enzalutamide
Boehringer Ingelheim
Prostatic Neoplasms, Castration-Resistant
10/19
06/23
WINGMEN, NCT05110495: Windows Trial of INsulin-like Growth Factor Neutralising Antibody Xentuzumab in MEN Scheduled for Radical Prostatectomy

Active, not recruiting
1
27
Europe
Xentuzumab
University of Oxford, Prostate Cancer UK, Boehringer Ingelheim
Prostate Cancer
01/23
12/23
NCT03099174: This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Completed
1
133
Europe, Japan, US, RoW
Xentuzumab, Abemaciclib, Letrozole, Anastrozole, Fulvestrant
Boehringer Ingelheim
Neoplasms, Breast Neoplasms
05/23
05/24

Download Options